S-1/A: Longeveron Inc. Seeks to Raise Capital Through Public Offering of Class A Common Stock and Warrants

Longeveron Inc. is offering up to 2,461,538 shares of Class A common stock along with warrants to fund clinical trials and general corporate purposes.

Summary

• Longeveron Inc., a clinical-stage biotechnology company, has filed an amendment to its registration statement for a public offering.
• The offering includes up to 2,461,538 shares of Class A common stock and accompanying Class A common warrants, as well as pre-funded warrants for certain purchasers.
• Each share of Class A common stock (or pre-funded warrant) is being sold with a Class A common warrant to purchase one share of Class A common stock.
• The assumed combined public offering price is $3.25 per share and accompanying warrant, based on the closing price on March 28, 2024.
• The Class A common warrants will have an exercise price to be determined and a term of five years.
• The offering will terminate on May 15, 2024, unless terminated earlier.
• The company intends to use the net proceeds for clinical and regulatory development of Lomecel-B, capital expenditures, and general corporate purposes.
• A reverse stock split of 1-for-10 was effected on March 26, 2024, impacting share numbers in the prospectus.
• The company received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement.
• H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is actively pursuing funding for its clinical programs, it also faces challenges such as Nasdaq compliance issues and a history of losses. The capital raise itself is a positive step, but the associated risks and uncertainties temper the overall outlook.

Positives

• The offering aims to provide funding for the clinical development of Lomecel-B, potentially leading to new treatments.
• The company has multiple potential mechanisms of action that promote tissue repair and healing with broad potential applications across a spectrum of disease areas.
• The company has completed a Phase 1 open -label study (ELPIS I) that supported the safety and tolerability of Lomecel -B for HLHS.
• The company has completed a Phase 2a AD clinical trial, known as the CLEAR MIND trial, which demonstrated positive results.
• The company has previously completed two U.S. clinical trials under FDA IND 016644.
• The company has been granted Rare Pediatric Disease (RPD) Designation, Orphan Drug Designation (ODD), and Fast Track Designation for Lomecel -B for treatment of infants with HLHS.

Negatives

• The company has a history of losses and may not be able to achieve profitability going forward.
• The company may not be able to raise additional capital necessary to continue as a going concern.
• The company has received notice from Nasdaq that the price of its Class A common stock does not satisfy the price minimum required for continued listing on the Nasdaq Capital Market.
• The company's reverse stock split may decrease the liquidity of the shares of its Class A common stock.
• The company's dual-class structure of its common stock may adversely affect the trading market for its Class A common stock.

Risks

• Investing in the company's securities involves a high degree of risk.
• The company may not raise the amount of capital it believes is required for its business plans.
• The company has broad discretion in how it uses the net proceeds of the offering.
• Raising additional capital may cause future dilution to the company's stockholders.
• The price of the company's Class A common stock may be volatile or may decline regardless of its operating performance.
• There may not be sufficient liquidity in the market for the company's securities in order for investors to sell their shares.
• The company will need to raise substantial additional funding.
• The company's reverse stock split may decrease the liquidity of the shares of its Class A common stock.
• The company's dual-class structure of its common stock may adversely affect the trading market for its Class A common stock.
• The company is an emerging growth company, and it cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make its common stock less attractive to investors.
• The issuance of additional stock in connection with acquisitions or otherwise will dilute all other stockholdings.
• The company has a history of losses, may not be able to achieve profitability going forward, and may not be able to raise additional capital necessary to continue as a going concern.

Future Outlook

The company intends to use the net proceeds from this offering for its ongoing clinical and regulatory development of Lomecel-B for the treatment of several disease states and indications, including HLHS and Alzheimers Disease; obtaining regulatory approvals; capital expenditures, working capital and other general corporate purposes.

Industry Context

Longeveron is operating in the competitive biotechnology industry, focusing on regenerative medicines and cell-based therapies. The company's focus on Lomecel-B for HLHS, Alzheimer's disease, and aging-related frailty places it within the growing market for therapies addressing unmet medical needs in these areas.

Comparison to Industry Standards

• The company's approach to developing Lomecel-B, an allogeneic Mesenchymal Stem Cell (MSC) formulation, aligns with industry trends in regenerative medicine.
• The company's focus on HLHS, AD, and Aging-related Frailty is similar to other biotechnology companies targeting specific disease areas with novel therapies.
• The company's clinical trial strategy, including Phase 1, Phase 2, and Phase 3 trials, is consistent with industry standards for drug development.
• The company's collaborative arrangements and out-licensing opportunities are common strategies in the biotechnology industry for commercializing products.
• The company's intellectual property portfolio is a key asset, similar to other biotechnology companies relying on patents to protect their innovations.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees' job security is tied to the company's financial stability and success of clinical programs.
• Customers (patients) may benefit from the development of new therapies for HLHS, Alzheimer's disease, and aging-related frailty.
• Suppliers and creditors are dependent on the company's ability to meet its financial obligations.

Next Steps

• Complete the public offering of Class A common stock and warrants.
• Utilize the net proceeds to fund clinical and regulatory development of Lomecel-B.
• Continue ongoing Phase 2 clinical trial (ELPIS II) for HLHS.
• Pursue strategic collaborations for the advancement of Lomecel-B in addressing AD.
• Monitor and address Nasdaq compliance regarding minimum bid price requirement.

Key Dates

Keywords

Longeveron, Class A common stock, warrants, public offering, Lomecel-B, clinical trials, reverse stock split, Nasdaq, H.C. Wainwright, biotechnology, capital raise, HLHS, Alzheimer's disease